Introduction
Multiple myeloma (MM) is a B-cell malignancy characterized by clonal accumulation of malignant plasma cells in bone marrow (BM). The BM microenvironment plays a critical role in promoting MM cell growth, survival, migration and development of drug resistance. 1 These findings have provided a framework for novel therapeutic strategies targeting both tumor cells and their BM microenvironment. 1, 2 However, despite recent advances in the understanding of MM biology and the availability of new agents, such as thalidomide, 3 revlimid 4 and bortezomib, 5 which have improved responses and survival, 6 MM remains incurable and novel treatments are urgently needed. Atiprimod (Atip) is an Azaspirane cationic amphiphilic compound (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine), with anti-inflammatory activity in a number of experimental models of autoimmune disease and transplantation. 7, 8 Atip inhibits the inflammatory response and preserves bone integrity in murine models of rheumatoid arthritis (RA), [9] [10] [11] [12] targets macrophages, inhibits phospholipase A and C in rat alveolar macrophages 13, 14 and exhibits antiproliferative and antiangiogenic activities in human cancer models. [15] [16] [17] Importantly, we have previously reported that Atip inhibits MM cell growth, induces caspase-mediated apoptosis, blocks the phosphorylation of Jak2/STAT3 and NF-kB, and downregulates the antiapoptotic proteins BCL-2, Bcl-X l and Mcl-1 16, 17 in MM cells. To further explore the anti-MM potential of Atip, we here investigate the specific signaling pathways perturbated by Atip in IL-6 dependent (INA-6) as well as independent (OPM1) MM cells, and evaluate the in vivo activity of this agent in three different SCID mouse models of human MM that provides a preclinical framework for its clinical evaluation in MM patients.
Materials and methods

Drug
Atip was provided by Callisto Pharmaceuticals Inc. (New York, NY, USA) as powder, and was dissolved in PBS (GIBCO, Grand Island, NY, USA) at a final concentration of 10 mM and then stored in aliquots at À201 until use, to avoid multiple freezethaw cycles.
MM cell lines and primary patients cells
OPM1 and INA-6 human MM cell lines were kindly provided by Dr Edward Thompson (University of Texas Medical Branch, Galveston, TX, USA) and Burger 18 (University of ErlangenNuernberg, Erlangen, Germany), respectively. The IL-6 independent OPM1 was cultured in RPMI 1640 media (GIBCO) containing 10% fetal bovine serum, 2 mM L-glutamine (GIBCO), 100 U ml À1 penicillin and 100 mg ml À1 streptomycin (GIBCO). The IL-6 dependent INA-6 cell line was cultured in the presence of 2.5 ng ml À1 of human recombinant IL-6 (R&D Systems Inc., Minneapolis, MN, USA). BM aspirates were obtained from MM patients following informed consent, subjected to FicollHypaque density gradient centrifugation and mononuclear cells were separated and suspended in RPMI 1640 media (GIBCO) containing 20% fetal bovine serum, 2 mM L-glutamine (GIBCO), 100 U ml À1 penicillin and 100 mg ml À1 streptomycin (GIBCO). 
Cell proliferation assay
Colorimetric survival assay
Colorimetric assays were also performed to evaluate cell survival using a tetrazolium assay (CellTiter 96 Non-Radioactive Cell Proliferation Assay; Promega, Madison, WI, USA). MM cells (1 Â 10 4 per well) were incubated in 96-well plates in 100 ml RPMI media containing 10% fetal bovine serum, L-glutamine and antibiotics and treated as indicated. At the end of each treatment, cells were incubated with 150 ml dye solution and incubated at 37 1C for 4 h. A solubilization/stop solution was then added to each well under vigorous pipetting to dissolve the formazan crystals. Absorbance readings at a wavelength of a 570 nm were obtained with a spectrophotometer (Molecular Devices, Sunnyvale, CA, USA), and cell viability was estimated as percentage of untreated controls.
Gene expression and microarray data analysis
INA-6 and OPM1 cells (2 Â 10 6 ) were exposed to Atip at the IC 50 dose for 24 h. Total RNA was isolated utilizing an 'Rneasy' kit (Qiagen Inc., Valencia, CA, USA) and gene expression profile was evaluated using the HG-U133A array chip (Affymetrix, Santa Clara, CA, USA), representing approximately 33 000 human genes. GeneChip arrays were scanned on a Gene Array Scanner (Affymetrix). Normalization of arrays and calculation of expression value were performed using the DNA-Chip Analyzer. 19 The Invariant Set Normalization method was used to normalize arrays at probe level to make them comparable, and the model-based method was used for probe selection and to compute expression values. 19 These expression levels were assigned standard errors based on replicates, which were subsequently used to compute 90% confidence intervals of fold changes in inter-group comparisons. The lower confidence bounds of 'fold change' were consecutive estimates of the actual changed. Expression of key genes involved in apoptosis, adhesion, signal transduction and cell-cycle control was analyzed. We performed assays in duplicate and repeated each experiment twice.
Western blot analyses
INA-6 and OPM1 cells were exposed to Atip at the IC 50 dose for 12 or 24 h, harvested, washed and lysed using lysis buffer: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 10 mM sodium pyrophosphate, 5 mM EDTA, 1 mM ethylene glycol tetraacetic acid (EGTA), 2 mM Na 3 VO 4 , 5 mM NaF, 1 mM PMSF, 5 mg ml À1 leupeptin and 5 mg ml À1 aprotinin. Whole cell lysates (10-20 mg per lane) were subjected to SDS-PAGE separation, transferred to polyvinylidene difluriode (PVDF) membranes (Bio-Rad Laboratories, Hercules, CA, USA) and immunoblotted with anti-p-21 antibody (Cell Signaling, Beverly, MA, USA).
Pathway analysis
In order to analyze all cellular pathways modulated by Atip, we examined a number of genes with altered expression in known pathway networks using a network-mapping tool, the Ingenuity Systems Software (Ingenuity Systems, Mountain View, CA, USA), which is able to explore the most relevant networks of gene interactions from experimental data. A cutoff of 2 was set to identify genes with significant regulation (Focus Genes, Ingenuity Pathways analysis, 2003 release, Ingenuity Systems). The use of this stringent statistical threshold of 2, comparing treated versus control MM cells resulted in the identification of 1357 genes for INA-6 and 1372 for OPM1. The identified genes were mapped to all networks available in the Ingenuity database and were then ranked by score. The score is the probability that a collection of genes equal to or greater than the number in a network could be achieved by chance alone. Genes with maximum score are the most significantly modulated. Pathways with the higher score of 38 for INA-6 and 37 for OPM1 have been used to form a composite network, representing the underlying biology of the process.
In vivo activity: animals CB-17 SCID-mice were obtained from Taconic (Germantown, NY, USA), maintained and monitored in our animal research facility. All animal studies were conducted according to protocols approved by the Institutional Animal Care and Use Committee. Animals were killed when their tumors reached 2 cm in diameter or when paralysis or major compromise in their quality of life occurred.
Human MM xenograft murine model CB 17 SCID-mice were subcutaneously (s.c.) inoculated in the interscapular area with 2.5 Â 10 6 OPM1 cells in 100 ml of RPMI-1640 medium. When the tumor was measurable, approximately 3 weeks after the MM cells injection, mice were treated with Atip intraperitoneally (i.p.) at 20, 30 and 50 mg kg À1 on alternate days for 7 days. Tumor size was measured every 3 days in two dimensions using an electronic caliper, and the tumor volume was calculated using the following formula: V ¼ 0.5a Â b 2 , where a and b are the long and short diameter of the tumor, respectively.
SCID-hu models of human MM
Human fetal long bone grafts were s.c. implanted into SCID mice (SCID-hu), as previously described. 20, 21 In the SCID-hu INA-6 model, 4 weeks following bone implantation, 2.5 Â 10 6 INA-6 MM cells were injected directly into the human BM cavity in the SCID-hu mice in a final volume of 100 ml of RPMI-1640 medium. An increase in the levels of soluble human IL-6 receptor (shuIL-6R), released by INA-6 cells, was used as an indicator of MM cell growth and burden of disease in SCID-hu mice. Mouse sera were serially measured for shuIL-6R levels by an enzyme-linked immunosorbent assay (ELISA, R&D Systems Inc.). Mice developed measurable serum shuIL-6R approximately 4 weeks following INA-6 cell injection, and were then treated i.p. with vehicle alone or Atip at 40 mg kg À1 every other day for 3 weeks. Following treatments, blood samples were collected and analyzed.
In the SCID-hu mice injected with primary patient MM cells, mice were produced as previously described, 20, 21 and received 5 Â 10 6 BM cells from a MM patient, directly into the human bone chip in a final volume of 100 ml of RPMI-1640 medium, approximately 4 weeks following the bone implant. Increasing levels of circulating human paraprotein in mice sera were monitored and used as an indicator of tumor engraftment and MM growth. Levels of human immunoglobulin G (IgG), k and l light chains were determined by ELISA (Bethyl, Montgomery, TX, USA). When MM engraftment was detectable (IgG k or l positive), mice were treated with i.p. Atip (50 mg kg À1 ) or vehicle alone (PBS) on alternate days for 4 weeks.
Histological analysis
Analysis was performed on decalcified fetal bone chips retrieved from SCID-hu mice, following 3 months of weekly i.p. treatment with Atip at 40 mg kg À1 . Tissues were fixed in 3.7% formaldehyde/PBS overnight at 4 1C, processed, embedded in paraffin and sections were obtained. In situ hybridizations were performed using complementary 35S-labeled riboprobes as described previously. 22 
Statistical analysis
Statistical significances of differences were determined by using Student's t-test. The minimal level of significance was Po0.05.
Results
Perturbation of growth and survival genes by Atip
We have previously reported that Atip induces in vitro cytotoxicity via poly (ADP-ribose) polymerase (PARP) cleavage and caspase-mediated apoptosis in conventional drug-sensitive (MM.1S, RPMI8226, U266, INA-6) and resistant (MM.1R, RPMI-LR5) MM cell lines as well as primary tumor cells with an IC 50 in the range of 0.5-1.25 mM.
16 As IL-6 dependent (INA-6) and independent (OPM1) MM cells are used in our animal models, we first confirmed, using (Figures 1a and b) . To characterize the molecular sequelae triggered by Atip in MM cells, we evaluated changes in global gene expression profile in MM cells following 24 h exposure to the drug. Both INA-6 and OPM1 cells were treated with Atip at the IC 50 dose for 24 h, RNA isolated and the gene expression profile analyzed using HG-U133A GeneChip arrays (Affymetrix), which represents approximately 33 000 human genes. We focused on expression pattern of genes modulated in Atip-treated versus control MM cells. As shown in Figure 2 , demonstrating data as fold change, in both INA-6 and OPM1 cells, significant upregulation was observed in genes involved in apoptosis (p21, TNF15, TRAILR3, SEMA6A, ADRA1A and v-Fos), whereas downregulation occurred in genes involved in cell cycle (TGF-b receptor II, PTPRN2 and PTPN21), adhesion (integrin b1 and 8, cadherin 3, cadherin F9 and cadherin F8) and cell signaling (MAPK5 and Nuclear receptor 2C1) pathways. Interestingly, genes involved in bone development, such as DLX5, GDF8, MMP1, LECT2, were upregulated and genes implicated in negative regulation of bone morphogenic protein signaling pathways, such as SMADspecific E3 ubiquitin protein ligase 1 and FGFR3 were downregulated. Since our gene array data showed that p21 is the most modulated gene in both cell lines (more than 6-fold change), we performed an immunoblot analysis to evaluate its protein levels in MM cells. As shown in Figure 3 , Atip at the IC 50 dose upregulates p21 at 12 and 24 h in both INA-6 and OPM1 cells, confirming the gene expression changes as well as its role in the apoptotic process induced by Atip.
Pathway analysis of representative genes affected by Atip
In order to analyze biological pathways affected by Atip, all genes were subjected to Ingenuity Pathway Analysis. As seen in Biological pathways and in vivo anti-MM activity of Atiprimod P Neri et al Figure 4 , in both cell-lines G-protein, Integrin, wnt/b-catenin signaling pathways as well as IL-6, ERK/MAPK, TGF-b, FGF, IGF-1 and cell-cycle regulation pathways were most modulated following Atip treatment. In particular, the bar graph shows the number of genes modulated for each pathways by Atip in both cell lines as compared to untreated cells, based on significance obtained by the Ingenuity analysis. The highest scoring networks were selected for further analysis based on significance (P-value) and combined to form a composite network representing the overall molecular effect of Atip in each cell line. As shown in Figure 5 , representing the principle nodes modulated by Atip in both cell lines, the genes that were most modulated were those commonly involved in cell-cycle arrest and apoptosis (TADA3L, p21, AP2A2, MAF, JUN, ERG, PPARG), integrin signaling (ITGB5, IGFBP5, ITGB8 and FN1), signal transduction (IL1R1, MAP3K13, ADRA1D, ABCC3, PDGFRB), FGF regulation (FGF2, FGFR1) and TGF-b signaling and development (GDF8, GDF15, TGF-b1, TGF-b2, SPARC, Bone morphogenic protein 2), ( Figure 5 ). Taken together these data identify critical pathways that can explain the drug's growth inhibitory activity.
In vivo activity of Atip in a subcutaneous and SCID-hu models of MM À1 showed 31, 48 and 55% growth inhibition, respectively, compared with control group, demonstrating that Atip has considerable in vivo activity against human MM.
In order to study the activity of Atip on MM cells growing in the context of a human BM microenvironment, we next used a SCID-hu model in which IL-6 dependent INA-6 cells are directly injected into previously implanted human fetal bone chip in SCID-mice. 23, 24 A cohort of 10 SCID-hu mice bearing human bones engrafted with INA-6 cells were treated i.p. on alternate day with Atip (40 mg kg
À1
, n ¼ 5) or vehicle alone (PBS, n ¼ 5), respectively, for 3 weeks. In this model, the anti-MM activity is analyzed by measuring the serum shuIL-6R levels, secreted by INA-6 cells. As shown in Figure 6b , Atip treatment induced significant tumor regression as compared with control mice (78% reduction in shuIL-6R, P ¼ 0.03). To evaluate the in vivo efficacy of Atip against primary patient derived MM cells, we treated SCID-hu mice previously engrafted with explanted 
Effect of Atip on MM induced bone resorption
Previous studies have shown the ability of Atip to inhibit bone resorption in an in vitro assay (Badger et al., 1996, private communication) and protect bones from the destructive effects of the arthritis. 11 Based on these preliminary studies and our gene array data, we evaluated the in vivo effects of this drug on bone formation and resorption. Four SCID-hu mice, previously implanted with the bone chip, received weekly i.p. injections of Atip 40 mg kg À1 for 3 months. Mice were killed, bone implant retrieved and analyzed by in situ hybridization. As shown in Figure 6d , Atip treatment significantly decreases the osteoclasts Table 1 shows, as fold change, genes related to the BMP pathways, modulated following Atip treatment in both cell lines.
Biological pathways and in vivo anti-MM activity of Atiprimod P Neri et al number in Atip-treated mice compared to the control group, suggesting effect of Atip on bone remodeling. In particular, the number of multinucleated TRAP-positive cells was 250 in human rudiments from control mice, bearing MM cells but treated with vehicle alone and 75 per field (P ¼ 0.03) in mice treated with Atiprimod when compared to the control (Figure 6e) . Finally, the Table 1 shows, as fold change, genes related to the bone morphogenic protein pathways, modulated following Atiprimod treatment in both cell lines when compared to the control. In particular, significant upregulation was observed in several genes, members of the bone morphogenetic protein (BMP) family, involved in bone development, such as BMP-1, BMPR1A, BMP-2, BMP-5, GDF15, GDF8, GDF5 and as well as in genes implicated in the prevention of bone resorption, such as calcitonin (CALCA) and osteoprotegerin (OPG).
Discussion and conclusion
In the past few years, considerable progress has been made in the development of new drugs for MM treatment by the identification of key molecular mechanisms that play a critical role in the growth and survival of this cancer. A complex network of cytokines, chemokines and cell surface molecules modulate the interaction between MM cells and the BM microenvironment thereby regulating MM cell proliferation, growth, survival and development of drug resistance. [25] [26] [27] This has led to development of novel agents that target not only MM cells, but also the BM milieu, and are able to overcome resistance to conventional therapies. 28 In this report, we investigated in vitro molecular mechanisms and in vivo activity of Atip, as a therapeutic agent in MM. Previous studies performed in our laboratory as well as by others have demonstrated in vitro activity of Atip on MM cell lines and its ability to block Jak2/STAT3 and NF-kB, signaling pathways which play an important role for MM growth and survival, 16, 17 but its effect on expression profile has not been previously explored. Based on these data, in this study, we selected 24 h a time point that captures maximal effect of the drug and used IL-6 dependent (INA-6) and independent (OPM1) MM cells in order to focus on changes in gene expression profiles induced by Atip. We identified a specific pattern of transcriptional events induced by Atip in MM cells that leads to eventual growth arrest and apoptosis. Atip was found to induce pro-apoptotic genes (TNF15, TRAILR3, p21 and v-Fos) and to downregulate transcripts essential for the cell-cycle progression (PTPNR21, PTPRN2, TGF-b2), adhesion and signal transduction (ITGB4 and 8, CDH3 and CDHF9, MAPK5 and nuclear receptor 2C1). The upregulation of transcripts implicated in apoptosis, such as the death ligands TNF15, and TRAILR3, are consistent with previous studies showing the pro-apoptotic role of these molecules. 29, 30 Moreover, the upregulation of p-21, a known mediator of cellcycle arrest and apoptosis, 31 shown by both gene array data and western blot analysis, could partially explain the activity of Atip on MM cells. Using the Ingenuity Pathway Analysis on cells treated with Atip, we identified genes and pathways that are of specific interest in MM biology. Specifically, the pathway mapping analysis identified the modulation of genes involved in integrin signaling (ITGB5, IGFBP5, ITGB8 and FN1), important in mediating MM cell adhesion to the stroma 32 and in the development of drug resistance. 33 Similarly, we observed modulation of FGF and TGF-b signaling (FGF2, FGFR1 and TGFb2, GDF8, GDF15, TGF-b1, TGF-b2, SPARC and BMP2) involved in promoting MM cell growth and survival 34 which may contribute to the overall effect of Atip on MM cells. Taken together our data show the ability of Atip to perturb critical pathways that may explain the drug's growth inhibitory activity in MM and establish a framework to design combination therapies with conventional and/or novel antitumor agents. Importantly, we confirmed the in vivo activity of Atip using three different murine models of human MM, including a conventional subcutaneous model of human MM and two different SCID-hu models that engraft human MM cells in the context of their specific human BM milieu. Whereas the subcutaneous xenograft model confirmed in vivo activity of Atip in MM and established its dose and activity, the SCID-hu INA-6 model, 23 confirmed the drug's ability to overcome the protective effects of the BM milieu on MM cell growth, survival and drug resistance. 2 The drug's activity in the SCID-hu model using the primary patient MM cells, a model that accurately recapitulates the human disease, reconfirmed the activity of Atip against human MM engrafted in the context of human BM microenvironment. Therefore, our in vivo data demonstrated the ability of Atip to induce a dose-dependent antitumor effect in all three murine models. Bone disease is a significant clinical component of MM presentation. 35 Lytic bone lesions and their associated complications are the major causes of morbility in MM. The predominant feature of this complication is an increased osteoclast number and activity, leading to increased bone resorption along with decreased osteoblast activity. 36 Of particular interest was the observed reduction in the number of osteoclasts following Atip treatment and the upregulation of several genes related to the BMP pathways in MM-treated cells versus control. In particular Atip was found to induce several members of the BMP family , critical factors to promote cartilage and bone formation. 37 Similarly, we observed upregulation of the soluble decoy receptor OPG and CALCA involved in the negative regulation of bone resorption, 38 suggesting a potential role of this agent in MM bone disease. Based on these data, a detailed evaluation of Atip's effects on osteoclast number and function at molecular and signaling level is warranted to define its use in bone disease. In conclusion, the present report demonstrates the in vitro anti-MM activity of Atip; it delineates biological targets, defines molecular pathways triggered by this drug and confirms strong in vivo evidence of its activity in preclinical models of MM. Taken together our data provide a rationale for its clinical evaluation in MM. 
